The present invention relates to a medical instrument for the targeted introduction of a substance into a body cavity and to a tool (1) therefor. According to the invention, the tool (1) has a shaft (2) with a lumen (6), on the distal end (1″) of which is situated a nozzle head (3) with at least two nozzles (4), wherein the nozzles (4) are spaced from each other at an angle of less than 180° and equally relative to a centre axis (M) of the shaft (2).

The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.

An aerosol unit for an aerosol dispenser, which aerosol unit comprises an axially oriented body, having a distal inlet part and a proximal outlet part; a carrier member arranged in the body, transversally to the axis between the inlet part and the outlet part; and wherein the carrier member comprises through-holes which place the inlet part in fluid communication with the outlet part, and wherein the carrier member is insert-moulded into the body such that a contact surface between the carrier and the body forms an air-tight seal.

A device comprising: a dispenser (1) comprising a reservoir (2) containing the fluid product, a dispensing head (3) provided with a dispensing orifice (4), able to move axially relative to the reservoir (2), and a dispensing member (5) actuated when the reservoir (2) is moved axially upwards relative to said dispensing head (3), an inner body (10) comprising a hollow cylinder (11) receiving said dispenser (1), an outer body (20) receiving said inner body (10), a push member (30), and an actuating system; said push member (30) being movable relative to said inner body (10) between a rest position and an actuating position, a spring (40) being interposed between said inner body (10) and said push member (30), said spring (40) being compressed in the rest position of said push member (30) in order to urge it towards its actuating position, said actuating system comprising a reset gear (50), a pawl (60), a floating wheel (70), a motor wheel (75), and a motor (80), wherein: said pawl (60) interacts with said push member (30) to lock it in the rest position, said pawl (60) being moved from its locked position towards a release position by said floating wheel (70) when the motor (80) rotates in a first actuating direction, and said reset gear (50) interacts with said push member (30), said reset gear (50) being moved by said floating wheel (70) when the motor (80) rotates in a second reset direction in order to return said push member (30) into its rest position.

The present invention relates to a closed system intranasal treatment device that is preferably in round, square, rectangular, triangular prism, quadrilateral, pentagon etc. form and that ensures the person who will use it gets maximum efficiency from the drug by creating a closed structure by completely wrapping noses of pediatric, adult and geriatric patient groups and preventing the drug from passing out of the system and maximizes patient compliance, in which all liquid pharmaceutical compositions in the state of the art are applicable.

The present disclosure provides aerosol delivery devices having a variety of configurations and arrangements. Some aspects of the disclosure provide aerosol delivery devices having a first pump configured to deliver a flow of air; a second pump configured to deliver a flow of liquid; and a nozzle configured to receive the flow of air and the flow of liquid and output the liquid in an atomized form.

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

A vaporizing article, comprises a vaporizer drive circuit; one or more memories configured to store a percentage of at least one constituent in an inhalation media, one or more compensation values for at least one compensation category for the at least one constituent, and instructions; and a control circuit comprising a processor coupled with the one or more memories configured to run the instructions, the instructions configured to cause the processor to: receive a dose target for a constituent; determine whether to perform compensation for an inhalation media dose in order to ensure the dose target is met; when compensation is to be performed, determine the properly compensated inhalation media dose based on an associated compensation value for the constituent; and control the vaporizer drive circuit so as to dispense a compensated dose of the inhalation media.

The present invention provides a delivery device for intranasal administration of topical therapeutic agents to a desired site within a nasal cavity. The delivery device, in some embodiments, comprises a housing defining an interior and adapted to contain a supply of at least one therapeutic agent. The delivery device further includes a flexible connector, which is in fluid communication with the supply in the housing. A distributor, which is also integrally formed with the connector, is also provided. The distributor includes a proximal end that is in fluid communication with a distal end of the connector, and is adapted to receive the supply of the at least one therapeutic agent delivered by way of a conduit. The distributor further includes a distal end defining an outlet configured to diffuse the therapeutic agent when delivered to the treatment site.

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.